SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

The year in cardiology 2017: heart failure

█ Current opinion

Lars H. Lund1,2*, Lars Køber3, Karl Swedberg4,5 and Frank Ruschitzka6
1FoU Tema Hjärta Kärl, Norrbacka, S1: 02, 17176 Stockholm, Sweden;
2Department of Medicine, Karolinska Institutet, Heart and Vascular Theme, Karolinska University Hospital, Stockholm, 171776 Stockholm, Sweden;
3Department of Cardiology, Rigshospitalet, University of Copenhagen, København Ø, Denmark;
4Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, 405 30 Gothenburg, Sweden;
5National Heart and Lung Institute, Imperial College, London SW7 2AZ, UK; and
6University Heart Centre Zurich, Rämistrasse 100, 8091 Zürich, Switzerland


The 2016 European Society of Cardiology (ESC) heart failure (HF) guidelines brought to the fore new recommendations for the management of HF with reduced ejection fraction (HFrEF; EF <40%); introduced a new term: HF with mid-range EF (HFmrEF) for the previously denoted ‘grey area’ corresponding to EF 40–49%; highlighted the continued lack of evidence based interventions in HFmrEF and HF with preserved EF (HFpEF; EF ≥40%); and introduced the concept of early intervention in acute HF (AHF). Here we summarize data from autumn 2016 to autumn 2017 that analyses implementation and utilization of existing proven therapy in HFrEF; additional neutral trials in HFpEF but detailed characterization of and potential efficacy of therapy in HFmrEF; further disappointing trials in AHF; and growing evidence in favour of treating comorbidities.


click here to read the full article

click here to read the pdf